We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
Read MoreHide Full Article
Stryker Corporation (SYK - Free Report) is well poised for growth backed by robust performing robotic-arm assisted surgery platform — Mako and diversified product portfolio. However, pricing pressure remains a headwind.
Shares of Stryker have gained 7.5%, compared with the industry’s growth of 1.2% on a year-to-date basis. Meanwhile, the S&P 500 Index has rallied 8% in the same timeframe.
Stryker, with a market capitalization of $84.75 billion, is one of the world’s largest medical device companies operating in the orthopedic market. It anticipates earnings to improve 9.4% in the next five years. Moreover, it has a trailing four-quarter earnings surprise of 3.3%, on average.
Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).
What’s Deterring the Stock?
An unfavorable pricing environment poses a persistent threat to Stryker’s core businesses. In fact, pricing in second-quarter 2020 had an impact of 0.2% on the top line. Consequently, pricing pressure continues to weigh on its performance.
What’s Favoring the Stock?
Mako is Stryker’s robotic-arm assisted surgery platform. The company continues to witness strong demand for Mako and healthy order book despite financial constraints stemming from the COVID-19 pandemic courtesy of the platform’s unique features. This, in turn, positions the company well to sustain momentum in robot sales and recon share market gains. For 2020, the company’s Mako order book remains solid and is in sync with its aim of continued share gains in both hips and knees. In fact, the company saw promising number of Mako installations in the United States in the second quarter.
Additionally, Stryker has a diversified product portfolio. Its wide range of products provide the company immunity against any significant sales shortfall during economic turmoil. Its significant exposure in robotics, Artificial Intelligence for health care and Medical Mechatronics has provided the company with a competitive edge in the MedTech space. Stryker’s portfolio includes products like Hip, Knee and Mako robotic-arm assisted surgeries.
Apart from these, Stryker has been one of the earliest adopters of the 3D printing technology. The company’s FDA-approved Tritanium TL Curved Posterior Lumbar Cage is a 3D-printed interbody fusion cage intended for use as an aid in lumbar fixation.
In second-quarter 2020, Stryker’s adjusted R&D expenses were 7.6% of net sales. Per management, this is likely to drive new product launches.
Estimates Trend
For 2020, the Zacks Consensus Estimate for revenues is pegged at $13.95 billion, indicating a decline of 6.2% from the prior-year quarter. The same for earnings stands at $6.29, suggesting a slump of 23.9% from the year-ago reported figure.
Stocks to Consider
Some better-ranked stocks from the broader medical space include Biolase, Inc. (BIOL - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) . While both Biolase and Boston Scientific carry a Zacks Rank #2 (Buy), Thermo Fisher sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Biolase has a projected long-term earnings growth rate of 15%.
Boston Scientific has an estimated long-term earnings growth rate of 10%.
Thermo Fisher has a projected long-term earnings growth rate of 15.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Here's Why You Should Hold on to Stryker (SYK) Stock Now
Stryker Corporation (SYK - Free Report) is well poised for growth backed by robust performing robotic-arm assisted surgery platform — Mako and diversified product portfolio. However, pricing pressure remains a headwind.
Shares of Stryker have gained 7.5%, compared with the industry’s growth of 1.2% on a year-to-date basis. Meanwhile, the S&P 500 Index has rallied 8% in the same timeframe.
Stryker, with a market capitalization of $84.75 billion, is one of the world’s largest medical device companies operating in the orthopedic market. It anticipates earnings to improve 9.4% in the next five years. Moreover, it has a trailing four-quarter earnings surprise of 3.3%, on average.
Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).
What’s Deterring the Stock?
An unfavorable pricing environment poses a persistent threat to Stryker’s core businesses. In fact, pricing in second-quarter 2020 had an impact of 0.2% on the top line. Consequently, pricing pressure continues to weigh on its performance.
What’s Favoring the Stock?
Mako is Stryker’s robotic-arm assisted surgery platform. The company continues to witness strong demand for Mako and healthy order book despite financial constraints stemming from the COVID-19 pandemic courtesy of the platform’s unique features. This, in turn, positions the company well to sustain momentum in robot sales and recon share market gains. For 2020, the company’s Mako order book remains solid and is in sync with its aim of continued share gains in both hips and knees. In fact, the company saw promising number of Mako installations in the United States in the second quarter.
Additionally, Stryker has a diversified product portfolio. Its wide range of products provide the company immunity against any significant sales shortfall during economic turmoil. Its significant exposure in robotics, Artificial Intelligence for health care and Medical Mechatronics has provided the company with a competitive edge in the MedTech space. Stryker’s portfolio includes products like Hip, Knee and Mako robotic-arm assisted surgeries.
Apart from these, Stryker has been one of the earliest adopters of the 3D printing technology. The company’s FDA-approved Tritanium TL Curved Posterior Lumbar Cage is a 3D-printed interbody fusion cage intended for use as an aid in lumbar fixation.
In second-quarter 2020, Stryker’s adjusted R&D expenses were 7.6% of net sales. Per management, this is likely to drive new product launches.
Estimates Trend
For 2020, the Zacks Consensus Estimate for revenues is pegged at $13.95 billion, indicating a decline of 6.2% from the prior-year quarter. The same for earnings stands at $6.29, suggesting a slump of 23.9% from the year-ago reported figure.
Stocks to Consider
Some better-ranked stocks from the broader medical space include Biolase, Inc. (BIOL - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) . While both Biolase and Boston Scientific carry a Zacks Rank #2 (Buy), Thermo Fisher sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Biolase has a projected long-term earnings growth rate of 15%.
Boston Scientific has an estimated long-term earnings growth rate of 10%.
Thermo Fisher has a projected long-term earnings growth rate of 15.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>